A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.
Advanced Malignant Solid Tumors
DRUG: 9MW2821
Incidence of adverse events, Up to 28 days post last drug administration
Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Maximum observed concentration (Cmax), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Area under the concentration-time curve (AUC), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Half-life (t1/2), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Clearance (CL), 24 months|Objective Response Rate, ORR, Up to 24 months|Disease Control Rate, DCR, Up to 24 months|Duration of Response, DoR, Up to 24 months|Time to Response, TTR, Up to 24 months|Progression Free Survival, PFS, Up to 24 months|Overall Survival, OS, Up to 24 months|Incidence of Anti-Drug Antibody (ADA), ADA, Up to 24 months
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.